What is the recommended treatment for a urinary tract infection caused by Group B Streptococcus (Streptococcus agalactiae)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Group B Streptococcus Urinary Tract Infection

For Group B Streptococcus (GBS) urinary tract infections, treat with penicillin, ampicillin, or amoxicillin as first-line therapy, as all GBS strains remain universally susceptible to these agents. 1, 2, 3

First-Line Treatment Options

Penicillin-based antibiotics are the definitive treatment:

  • Ampicillin 500 mg PO/IV every 8 hours for 7-14 days 4
  • Amoxicillin 500 mg PO every 8 hours for 7-14 days 4
  • Penicillin G IV (dose adjusted for severity) 4

All GBS isolates demonstrate 100% sensitivity to penicillin and ampicillin, making these the unequivocal first choice. 1, 2, 3 The duration should be 7 days for uncomplicated cystitis and up to 14 days for complicated UTI or when prostatitis cannot be excluded in men. 4

Alternative Agents for Penicillin Allergy

For patients with penicillin allergy:

  • Vancomycin 1 g IV every 12 hours - if high risk for anaphylaxis (history of anaphylaxis, angioedema, respiratory distress, or urticaria with penicillin/cephalosporin) 4
  • Nitrofurantoin 100 mg PO every 6 hours - for uncomplicated cystitis only 4, 2
  • Cefazolin 2 g IV initial dose, then 1 g IV every 8 hours - if NOT high risk for anaphylaxis 4

All GBS strains remain 100% sensitive to vancomycin, making it the safest alternative for severe penicillin allergy. 1, 3 Nitrofurantoin shows excellent activity (98% sensitivity) and is particularly appropriate for simple cystitis. 2

Agents to AVOID

Do not use the following due to high resistance rates:

  • Clindamycin - 13-77% resistance reported 1, 3
  • Erythromycin - 25-36% resistance reported 1, 2
  • Azithromycin - 31-44% resistance reported 2
  • Tetracycline - 81-88% resistance reported 2, 3

The high resistance rates to macrolides and clindamycin make these agents unreliable without susceptibility testing. 1, 3 Even when susceptibility testing suggests sensitivity, these should be avoided given superior alternatives exist. 2

Special Considerations for Pregnancy

Pregnant women with GBS bacteriuria require specific management:

  • Treat ANY level of GBS bacteriuria (regardless of colony count) with appropriate antibiotics at time of diagnosis if symptomatic 5
  • All pregnant women with documented GBS bacteriuria (any CFU/mL) should receive intrapartum antibiotic prophylaxis during labor: Penicillin G 5 million units IV initial dose, then 2.5-3.0 million units IV every 4 hours until delivery 4
  • Do NOT re-screen these women in third trimester - they are presumed GBS colonized 5
  • Do NOT treat asymptomatic bacteriuria with colony counts <100,000 CFU/mL outside of labor 4, 5

GBS bacteriuria in pregnancy (2-4% of pregnancies) indicates heavy colonization and mandates intrapartum prophylaxis to prevent neonatal early-onset GBS disease. 4

Duration of Therapy

Treatment duration based on clinical syndrome:

  • Uncomplicated cystitis: 7 days 4
  • Complicated UTI: 7-14 days (14 days for men when prostatitis cannot be excluded) 4
  • Pyelonephritis: 7-14 days with β-lactams 4

Shorter courses (5-7 days) may be considered when the patient has been afebrile for at least 48 hours and is hemodynamically stable. 4

Key Clinical Pitfalls

Important caveats to avoid treatment failure:

  • GBS UTI signals need for screening for urinary tract abnormalities - 60% of non-pregnant adults with GBS UTI have underlying urological abnormalities 6
  • Identify and treat reservoirs (vagina, urethra, gastrointestinal tract) to prevent recurrence 7
  • GBS accounts for only 2% of UTIs but is associated with poor clinical outcomes in 18% despite treatment 6
  • Multidrug resistance is present in 33.6% of GBS UTI isolates, though this does not affect penicillin/ampicillin sensitivity 8
  • Women aged 25-34 years have nearly twice the risk of GBS UTI compared to younger women 3

References

Research

Antibiotic resistance patterns of group B streptococcal clinical isolates.

Infectious diseases in obstetrics and gynecology, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of group B streptococcal bacteriuria in pregnancy.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2012

Research

Group B Streptococcus: a cause of urinary tract infection in nonpregnant adults.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.